Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223317 | 1.00 | MEN1 (0.49) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL347096 | 1.00 | MEN1 (0.49) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL25381545 | 0.93 | TDP1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL15069849 | 0.87 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL1105702 | 0.85 | PCSK9 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL6563149 | 0.85 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL570033 | 0.85 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL18495370 | 0.85 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL22731060 | 0.85 | MEN1 (0.44) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL21202376 | 0.84 | MEN1 (0.47) | MEN1GAAKMT2ATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| WO-2026101971-A2 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4731213-A2 | COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS | Blossomhill Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4705308-A1 | EGFR INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4396191-B1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3822276-B1 | HETEROCYCLIC COMPOUND AS TRK INHIBITOR | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| CN-101163693-A | Antibacterial piperidine derivatives | ASTRAZENECA AB (SE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1863812-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2007-12-12 | — | — | EP | disclosed |
| EP-1844062-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | Methylgene, Inc. (CA) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| WO-2006104356-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES, LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, IGF1R, PDGFRB | MEN1 2416/4885GAA 921/4885KMT2A 2199/4885 |
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR1 | MEN1 2106/4885GAA 4299/4885KMT2A 2095/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | MEN1 4138/4885GAA 1454/4885KMT2A 1037/4885 |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | MEN1 873/4885GAA 3793/4885KMT2A 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.